In Vivo Phage Display for the Identification of Muscle Homing Peptides to Improve the Delivery of Phosphorodiamidate Morpholino Oligomers for Duchenne Muscular Dystrophy Therapy
Nucleic Acid Therapeutics · 2025
DOI: 10.1177/21593337251371708 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2025. Verfasst von Anne-Fleur E Schneider und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Morpholinos, Peptides, Oligonucleotides, Antisense. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
The severe X-linked degenerative neuromuscular disease Duchenne muscular dystrophy (DMD) is caused by the loss of dystrophin through reading frame disruptive mutations in the DMD gene. Dystrophin protein is crucial for the stability of the muscle. Targeting specific exons with antisense oligonucleotides (ASO) will prevent inclusion of the exon during pre-mRNA splicing, which can restore the reading frame, facilitating the production of partially functional dystrophin proteins. For DMD, four ASOs of the phosphorodiamidate morpholino oligomer (PMOs) chemistry are FDA approved. It is anticipated that improved delivery to skeletal muscle and heart will lead to larger therapeutic results. With our research, we sought to identify muscle-homing peptides that can achieve increased delivery of ASOs to muscle or heart when conjugated to PMOs. We applied in vivo phage display biopanning mouse models for DMD to identify muscle-homing peptides while simultaneously negatively selecting peptides that home to unwanted organs, such as the kidney and liver. After confirmation of the muscle homing ability in vitro , we conjugated selected candidate peptides to PMOs to be tested in vivo , where we found that conjugation of one specific muscle homing peptide led to significantly improved delivery to muscle, with a small improvement in exon skipping and dystrophin restoration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
- Sarepta Therapeutics, Cambridge, Massachusetts, USA.
ORCID-Profile: Anne-Fleur E Schneider, Annemieke Aartsma-Rus
Zitieren
APA
Schneider, A. E., Winter, C. L. T., Mei, H., Jirka, S. M. G., Tan, X., Thompson, E. G., Ha, K., Mitra, A., Garcia, S., Luimes, M., Oliver, R., Morgan, K. Y., Guerlavais, V., & Aartsma-Rus, A. (2025). In Vivo Phage Display for the Identification of Muscle Homing Peptides to Improve the Delivery of Phosphorodiamidate Morpholino Oligomers for Duchenne Muscular Dystrophy Therapy. Nucleic Acid Therapeutics. https://doi.org/10.1177/21593337251371708
Vancouver
Schneider AE, Winter CLT, Mei H, Jirka SMG, Tan X, Thompson EG, et al. In Vivo Phage Display for the Identification of Muscle Homing Peptides to Improve the Delivery of Phosphorodiamidate Morpholino Oligomers for Duchenne Muscular Dystrophy Therapy. Nucleic Acid Therapeutics. 2025. doi:10.1177/21593337251371708
BibTeX
@article{Schneider2025,
author = {Schneider, Anne-Fleur E and Winter, Christa L Tanganyika-de and Mei, Hailiang and Jirka, Silvana M G and Tan, Xuyu and Thompson, Emily G and Ha, Kristin and Mitra, Anindita and Garcia, Stephanie and Luimes, Marleen and Oliver, Ryan and Morgan, Kathy Y and Guerlavais, Vincent and Aartsma-Rus, Annemieke},
title = {In Vivo Phage Display for the Identification of Muscle Homing Peptides to Improve the Delivery of Phosphorodiamidate Morpholino Oligomers for Duchenne Muscular Dystrophy Therapy},
journal = {Nucleic Acid Therapeutics},
year = {2025},
doi = {10.1177/21593337251371708}
}
EUVIMED